drugset
drugset / Trial / NCT05589584

N-acetyl Cysteine and Patients with Non-alcoholic Fatty Liver Disease

NCT05589584 ↗

Phase 3 Completed 60 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

Effect of N-acetyl cysteine on markers of oxidative stress and insulin resistance in patients with Non-alcoholic fatty liver disease

Timeline

Start
2022-11-01
Primary completion
2024-05-20
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 2400 mg —

Indications

NAFLD1